ProCE Banner Activity

TROPiCS-03 Phase II Basket Trial: Sacituzumab Govitecan as Second-line Therapy for Extensive-Stage Small-Cell Lung Cancer

Conference Coverage
Slideset

In a multicohort basket trial, sacituzumab govitecan showed activity in patients with extensive-stage small-cell lung cancer previously treated with first-line platinum-based chemotherapy and anti‒PD-1/PD-L1 therapy.

Released: October 24, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc